Profusa (PFSA) vs. The Competition Critical Contrast

Profusa (NASDAQ:PFSA) is one of 29 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it weigh in compared to its competitors? We will compare Profusa to similar businesses based on the strength of its analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Profusa and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Profusa Competitors	-672.41%	-133.75%	-59.01%

Institutional and Insider Ownership

9.8% of Profusa shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 11.4% of Profusa shares are held by company insiders. Comparatively, 18.4% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Profusa has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500. Comparatively, Profusa’s competitors have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Profusa and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Profusa Competitors	77	76	156	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 51.09%. Given Profusa’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Profusa has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Profusa and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Profusa	N/A	-$8.71 million	-0.90
Profusa Competitors	$59.54 million	-$32.15 million	4.18

Profusa’s competitors have higher revenue, but lower earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Profusa competitors beat Profusa on 10 of the 13 factors compared.

Profusa Company Profile

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.